Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 With Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

NCT05220722 is registered in ClinicalTrials.gov with TriSalus Life Sciences, Inc. as lead sponsor.

NCT NCT05220722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05220722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 With Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Lead sponsor
TriSalus Life Sciences, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 2, 2022
Completion date
July 31, 2024
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, intrahepatic cholangiocarcinoma